Attractive Market Despite Pricing Pressures

BMI View: Despite risks to the Czech Pharmaceutical market posed by upcoming healthcare reforms and unfavourable changes to pricing and reimbursement regimes, the market remains one of the most attractive in Central and Eastern Europe (CEE). While lower growth is expected in the Czech market compared with its larger regional neighbour Poland, the industry has escaped large-scale cuts to reimbursement spending like those set to be introduced in Hungary.[1] BMI maintains that high per-capita drug market expenditure and a relatively high penetration of patented drugs continue to make this market attractive to international drugmakers.

To read the full article, please choose one of the following options: